阿替利珠单抗用于肉瘤样肾细胞癌患者的辅助治疗:IMmotion010预设亚组分析
这项IMmotion010预设亚组分析纳入104例肉瘤样肾细胞癌患者,评估辅助阿替利珠单抗对比安慰剂的疗效与安全性。中位随访45个月时,两组无病生存期差异无统计学意义(HR 0.77,95%CI 0.44-1.4),安全性特征与non-sRCC患者相似。
要点
- 肉瘤样肾细胞癌亚组中,阿替利珠单抗组与安慰剂组无病生存期差异无统计学意义(HR 0.77,95%CI 0.44-1.4)
- 阿替利珠单抗组3/4级治疗相关不良事件发生率为2.7%(1例),安慰剂组为3.0%(2例)
- 肉瘤样肾细胞癌患者的安全性特征与non-sRCC患者相似
核心结论
- 在肉瘤样肾细胞癌患者中,辅助阿替利珠单抗与安慰剂的无病生存期差异无统计学意义。
- 肉瘤样肾细胞癌患者的安全性特征与non-sRCC患者相似。
研究设计与样本
- IMmotion010(NCT03024996)是一项随机、双盲、3期试验。
- 本分析为预设亚组分析,纳入104例肉瘤样肾细胞癌患者,评估疗效与安全性。
- 患者为手术后复发风险增高的局限性肾细胞癌。
主要发现
- 中位随访45个月时,阿替利珠单抗组(n=37)中位无病生存期不可评估(NE;95%CI 12个月-NE),安慰剂组(n=66)为23个月(95%CI 11-NE),HR 0.77(95%CI 0.44-1.4)。
- 肉瘤样肾细胞癌亚组中,3/4级治疗相关不良事件在阿替利珠单抗组发生1例(2.7%),安慰剂组发生2例(3.0%)。
- non-sarcomatoid组织学患者中,3/4级治疗相关不良事件在阿替利珠单抗组353例中54例(15%),安慰剂组317例中16例(5.0%)。
临床怎么用
- 在肉瘤样肾细胞癌患者中,阿替利珠单抗耐受性可,可能比安慰剂更有效,但原文指出这需要进一步研究。
局限性
- 原文指出阿替利珠单抗可能比安慰剂更有效,但该发现需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with sarcomatoid renal cell carcinoma (sRCC) have a poor prognosis. In the randomised, double-blind phase 3 IMmotion010 trial (NCT03024996), adjuvant atezolizumab did not demonstrate a disease-free survival (DFS) benefit versus placebo in the overall population of patients with locoregional renal cell carcinoma with an increased risk of recurrence following surgery. This prespecified subgroup analysis of efficacy and safety was completed in 104 patients with sRCC. Baseline characteristics were similar between treatment arms. At a median follow-up of 45 mo, the median DFS was not evaluable (NE; 95% confidence interval [CI], 12 mo-NE) in the atezolizumab arm (n = 37) and 23 mo (95% CI, 11-NE) in the placebo arm (n = 66; hazard ratio 0.77 [95% CI, 0.44-1.4]). In the sRCC subgroup, grade 3/4 treatment-related adverse events (TRAEs) occurred in one patient (2.7%) in the atezolizumab arm and two patients (3.0%) in the placebo arm. By comparison, 54 of 353 patients (15%) and 16 of 317 patients (5.0%) with non-sarcomatoid histology reported grade 3/4 TRAEs in the respective arms. In conclusion, the difference in DFS was not statistically significant between adjuvant atezolizumab and placebo in patients with sRCC. The safety profile was similar between patients with sRCC and non-sRCC. PATIENT SUMMARY: Patients with a specific type of locoregional kidney cancer (tumours with sarcomatoid features) were treated with atezolizumab or placebo after surgery. Slightly more patients treated with atezolizumab lived longer without the disease getting worse than those treated with placebo, although this finding was not statistically significant. The side effects were similar to those seen in patients with other types of kidney cancer treated with atezolizumab in the same study (IMmotion010). In patients with sarcomatoid kidney cancer, atezolizumab was tolerable and may be more effective than placebo, but this requires further study.
引用
- Karam JA, Uzzo R, Bex A, et al. Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010. Eur Urol Oncol. 2024. PMID: 38955577. doi:10.1016/j.euo.2024.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。